ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / VBIO / news
NXL (32) NUWE (33) NDRA (36) IRIX (27) ⌘ Pro Terminal →

Why VBIO Stock dropped -3.47% Today — RQD Quant Desk Flash

$0.53 -3.47% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.53

Valion Bio Inc. (VBIO) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $1.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VBIO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is VBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Valion Bio Inc. (NASDAQ: VBIO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $0.53 (-3.47% 1D, market cap $1.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, VBIO ranks #585 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does VBIO compare to NXL and NUWE in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), VBIO carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NXL (Nexalin Technology Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $1.8M) and NUWE (Nuwellis Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $2.3M). Among the 5-stock peer group, VBIO leads on earnings multiple (N/A) while VBIO leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VBIO?
▼

Per VBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001787740), Valion Bio Inc. generated $22.1M in revenue (+2735.2% YoY), -$8.9M in net income, and -$7.0M in free cash flow against $31.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.53 (-0.81%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510036
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (8)Whales (3)SEC (10)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.4% Base Target
$71 Bull$0 Base$0 Bear
📬 FREE VBIO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VBIO)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY VBIO SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (28% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 22.2 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
44
Grade D$1.55-23.2% Next Q
Q2 (-2Q)
41
Grade D$1.19-34.5% Next Q
Q3 (-1Q)
39
Grade E$0.78-32.1% Next Q
Current
36
Grade D-$0.53-8.3% Hist 90D α
Trajectory: D (44) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a VBIO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While VBIO currently carries a cautious 36/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.11) and Max Pain ($0.56) forces dealer call-delta covering toward $70.88.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VBIO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VBIO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 36%NO 64%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why VBIO Stock dropped -3.47% Today — RQD Quant Desk Flash

Valion Bio Inc. (VBIO) dropped -3.47% to $0.53, trading at 2% of its 52-week range ($0.52 – $67.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 2% of its 52-week range ($0.52 – $67.5) with RSI-14 at 22.2 (OVERSOLD (<32)).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.53 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live VBIO Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VBIO)

  • ✓Walkthrough of VBIO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
VBIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -97.97%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.62H $0.62L $0.53C $0.53VOL 220.0K
RES: $34.77SUP: $0.43SMA50: $2.11SMA200: $14.80
$54.13$39.60$25.07$10.54$-3.99RES $34.77SUP $0.43$0.532026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VBIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VBIO Butterfly Map → + Track VBIO →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +2735.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on VBIO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VBIO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VBIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VBIO)

Health Care Rank #585 of 1015 ⚔️ NXL vs VBIO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VBIO vs. NXL, NUWE, NDRA, IRIX)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Valion Bio Inc. (VBIO) ranks #585 by composite RQD confidence (36/100, grade D-) and #1014 by equity capitalization ($1.2M). Within this direct 5-issuer industry benchmark cohort, VBIO leads on earnings valuation at N/A trailing P/E, while VBIO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VBIO currently leads its immediate peer cohort in composite quantitative strength at 36/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
VBIO ACTIVE
Valion Bio Inc.
D- 36/100 — — -35.0% -3.47% $1.2M Benchmark Subject
NXL
Nexalin Technology Inc.
E 32/100 — 79.7% -35.0% -5.94% $1.8M /nxl-vs-vbio →
NUWE
Nuwellis Inc.
E 33/100 — 62.0% -35.0% -8.80% $2.3M /nuwe-vs-vbio →
NDRA
ENDRA Life Sciences Inc.
D- 36/100 — — -35.0% +1.05% $7.1M /ndra-vs-vbio →
IRIX
IRIDEX Corporation
E 27/100 — 36.5% -35.0% +1.33% $12.5M /irix-vs-vbio →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001787740 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Valion Bio Inc. (VBIO) reported GAAP revenue of $22.1M (+2735.2% vs. FY2024 revenue of $780.0K , and +1780.5% cumulative change since FY2023) , GAAP net income of -$8.9M, operating cash flow of -$7.0M, and free cash flow of -$7.0M (-22.9% YoY). On the balance sheet, VBIO closed FY2025 with $31.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $22.1M -$8.9M -$7.0M -$7.0M $31.6M —
FY2024 (FY) 2024-12-31 $780.0K -$5.7M -$5.7M -$5.7M $2.8M —
FY2023 (FY) 2023-12-31 $1.2M -$8.2M -$8.5M -$8.5M — —

3. VBIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Valion Bio Inc. (NASDAQ: VBIO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $0.53 (-3.47% 1D, market cap $1.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, VBIO ranks #585 in composite RQD confidence.

How does VBIO compare to NXL and NUWE in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), VBIO carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NXL (Nexalin Technology Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $1.8M) and NUWE (Nuwellis Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $2.3M). Among the 5-stock peer group, VBIO leads on earnings multiple (N/A) while VBIO leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VBIO?

Per VBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001787740), Valion Bio Inc. generated $22.1M in revenue (+2735.2% YoY), -$8.9M in net income, and -$7.0M in free cash flow against $31.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VBIO trading relative to its 50-day, 200-day, and 52-week technical levels?

VBIO last traded at $0.53 (-3.47% on volume of 97,943 shares), positioning the stock -74.88% below its 50-day simple moving average ($2.11) and -96.42% below its 200-day simple moving average ($14.80). Across its 52-week range of $0.52 to $67.50, VBIO sits at the 0.0% percentile with a 14-day RSI of 22.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.60).

Direct Sub-Reports: VBIO RQD Cockpit VBIO 12M Forecast VBIO Earnings & Move VBIO Dividends & DRIP VBIO Insiders & 13F VBIO Whale Options VBIO Profit Sankey VBIO News & Why
ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ SEC XBRL & RQD VERIFIED

VBIO — Valion Bio Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Valion Bio Inc. (VBIO) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.53 (-3.47% 1D, market capitalization $1.2M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Valion Bio Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. The profile identifies the company as a biotechnology issuer with a market capitalization of $0.0B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Valion Bio Inc. (VBIO) reported $22.1M in annual revenue (up from $780.0K in FY2024, +2735.2% YoY) and -$8.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.2M revenue, -$8.2M net income) through FY2025, VBIO scaled operating cash flow to -$7.0M and free cash flow to -$7.0M, backed by $31.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 36/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.52 – $67.50 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), VBIO carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can VBIO sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $22.1M and free cash flow of -$7.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is VBIO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

VBIO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Valion Bio Inc. (VBIO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to VBIO Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VBIO Bull vs. Bear Conversation Board — What's Your Call at $0.53?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VBIO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on VBIO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $0.67 (+21.8%)
📌 Pinned Debate

Reported cash rose to $12.6M in FY 2025 from $2.0M in FY 2024, and a $4.77 million financing plus a $100M shelf filing were announced.

Picked up a starter position in VBIO in my $100K Virtual Cash book at $0.55. Reported cash rose to $12.6M in FY 2025 from $2.0M in FY 2024, and a $4.77 million financing plus a $100M shelf filing were announced.. Trading inside a $0.52–$67.50 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Electromedical & Electrotherapeutic Apparatus multiples expand this quarter.

VolSurface_Trader 🐂 BULL

Both sides have a point here — VBIO's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $0.45 (-18.2%)
Spot @ $0.55

Revenue fell from $1.2M in FY 2023 to $0.0M in FY 2025 while FCF stayed negative, and the RQD score is 36 (D-).

Fading this rally in VBIO at $0.55. Revenue fell from $1.2M in FY 2023 to $0.0M in FY 2025 while FCF stayed negative, and the RQD score is 36 (D-).. With a beta of 1.0 and the stock sitting at $0.55 (52-wk range $0.52–$67.50), the easy multiple expansion is already priced in.

LIVE TAPE